Market revenue in 2023 | USD 147.1 million |
Market revenue in 2030 | USD 266.4 million |
Growth rate | 8.9% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Banks |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Therapeutics, Tools, Banks, Services |
Key market players worldwide | AstraZeneca PLC, Roche Holding AG, Integra Lifesciences Holdings Corp, Astellas Pharma Inc, Cook Group, Bayer AG, Pfizer Inc, Merck KGaA, Abbott Laboratories, Vericel Corp, Novartis AG ADR, GlaxoSmithKline |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to regenerative medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 76.75% in 2023. Horizon Databook has segmented the Mexico regenerative medicine market based on therapeutics, tools, banks, services covering the revenue growth of each sub-segment from 2018 to 2030.
Mexico is one of the largest biotechnology markets in Latin America. The country has emerged as a potential hub for biopharmaceutical products owing to the presence of skilled scientists, low manufacturing costs, and an advanced legal framework. Moreover, the high penetration of U.S.- based biotechnology companies in Mexico has supported the country’s biotechnology and biomanufacturing sectors.
In addition, the country’s government has prioritized growth and innovation in the biopharmaceutical space. Thus, growing biopharmaceutical and biotechnology industries in the country are anticipated to create high demand for regenerative medicine and gene therapies in the region and support market growth. Furthermore, researchers from Mexico are exploring applications of regenerative medicine in research and disease diagnosis, which is supporting the country’s market growth.
In Mexico, all stem cell therapies and gene therapies are regulated as regenerative therapies and are used to treat a range of disorders, including cancer, cardiovascular disorders, and neurological disorders. In addition, the country is one of the preferred treatment destinations for Americans and Canadians due to its low cost of treatment involving regenerative therapies.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico regenerative medicine market , including forecasts for subscribers. This country databook contains high-level insights into Mexico regenerative medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account